Targeting of sugar- and charge-modified albumins to fibrotic rat livers: The accessibility of hepatic cells after chronic bile duct ligation

Journal of Hepatology

Volumn 29, Issue 4, 1998, Pages 579-588

  Beljaars, Leonie ^a   Poelstra, Klaas ^a   Molema, Grietje ^a   Meijer, Dirk K F ^a  

^a Dept of Pharmacokin/Drug Delivery ^*

Author keywords

Bile duct ligation; Drug targeting; Lactosaminated albumin; Liver fibrosis; Mannosylated albumin; Neo glycoprotein; Pharmacokinetics; Succinylated albumin; Therapy

Indexed keywords

ALBUMIN; DRUG CARRIER; NEOGLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DRUG TARGETING; EXTRACELLULAR MATRIX; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER FIBROSIS; LIVER SINUSOID; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT;

EID: 0032191706     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80153-0     Document Type: Article

References (51)

1. 1. Johnson SJ. Extracellular matrix proteins and hepatic fibrosis. Hepatogastroenterology 1996; 43: 44-55.
2. 2. Friedman SL, Flier JS, Epstein F, Glickman R, Scheele G. Seminars in Medicine of the Beth Israel Hospital, Boston -The cellular basis of hepatic fibrosis - mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-35.
3. 3. Gressner AM. Liver fibrosis: perspectives in pathobiochemical research and clinical outlook. Eur J Clin Chem Clin Biochem 1991; 29: 293-311.
4. 4. Alcolado R, Arthur MJ, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci 1997; 92: 103-12.
5. 5. Rojkind M. Fibrogenesis in cirrhosis. Potential for therapeutic intervention. Pharmacol Ther 1992; 53: 81-104.
6. 6. Chojkier M, Brenner DA. Therapeutic strategies for hepatic fibrosis. Hepatology 1988; 8: 176-82.
7. 7. Wu J, Danielsson A. Inhibition of hepatic fibrogenesis: a review of pharmacologie candidates. Scand J Gastroenterol 1994; 29: 385-91.
8. 8. Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994; 69: 969-82.
9. 9. Berg CL, Gollan JL. Primary biliary cirrhosis: new therapeutic directions. Scand J Gastroenterol Suppl 1992; 192: 43-9.
10. 10. Aldersley MA, O'Grady JG. Hepatic disorders. Features and appropriate management. Drugs 1995; 49: 83-102.
11. 11. Sherlock S. Primary biliary cirrhosis: clarifying the issues. Am J Med 1994; 96: 27S-33S.
12. 12. Meijer DKF, Jansen RW, Molema G. Drug targeting systems for antiviral agents: options and limitations. Antiviral Res 1992; 18: 215-58.
13. 13. Meijer DKF, Molema G Targeting of drugs to the liver. Semin Liver Dis 1995; 15: 202-56.
14. 14. Fiume L, Busi C, Mattioli A. Targeting of antiviral drugs by coupling with protein carriers. FEBS Lett 1983; 153: 6-10.
15. 15. Fiume L, Mattioli A, Spinoza G. Distribution of a conjugate of 9-β-D-arabinofuranosyladenine 5′-monophosphate (araAMP) with lactosaminated albumin in parenchymal and sinusoidal cells of rat liver. Cancer Drug Delivery 1987; 4: 11-6.
16. 16. Van der Sluijs P, Bootsma HP, Postema B, Moolenaar F, Meijer DKE Drug targeting to the liver with lactosylated albumins. Does the glycoprotein target the drug, or is the drug targeting the glycoprotein? Hepatology 1986; 6: 723-8.
17. 17. Jansen RW, Olinga P, Harms G, Meijer DKF. Pharmacokinetic analysis and cellular distribution of the anti-HIV compound succinylated human serum albumin (Suc-HSA) in vivo and in the isolated perfused rat liver. Pharm Res 1993; 10: 1611-4.
18. 18. Franssen EJF, Jansen RW, Vaalburg M, Meijer DKF. Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules. Biochem Pharmacol 1993; 45: 1215-26.
19. 19. Jansen RW, Molema G, Ching TL, Oosting R, Harms G, Moolenaar F, et al. Hepatic endocytosis of various types of mannose-terminated albumins. What is important, sugar recognition, net charge or the combination of these features. J Biol Chem 1991; 266: 3343-8.
20. 20. Schwartz BA, Gray GR. Proteins containing reductively aminated disaccharides: synthesis and characterization. Arch Biochem Biophys 1977; 181: 542-9.
21. 21. Kataoka M, Tavassoli M. Synthetic neoglycoproteins: a class of reagents for detection of sugar-recognizing substances. J Histochem Cytochem 1984; 32: 1091-4.
22. 22. Jansen RW, Molema G, Pauwels R, Schols D, De Clercq E, Meijer DKF. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol Pharmacol 1991; 39: 818-23.
23. 23. Jansen RW, Schols D, Pauwels R, De Clercq E, Meijer DKF. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 1993; 44: 1003-7.
24. 24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
25. 25. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem 1956; 28: 350-6.
26. 26. Habeeb AFSA. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966; 14: 328-36.
27. 27. Kuipers ME, Huisman JG, Swart PJ, de Béthune M-P, Pauwels R, De Clercq E, et al. Mechanism of anti-HIV activity of negatively charged albumins: Biomolecular interaction with the HIV-1 envelope protein gp120. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 419-29.
28. 28. Maeda H, Ishida N, Kawauchi H, Tuzimura K. Reaction of fluorescein-isothiocyanate with proteins and aminoacids. J Biochem 1969; 65: 777-83.
29. 29. Jobbágy A, Király K. Chemical characterization of fluorescein isothiocyanate-protein conjugates. Biochim Biophys Acta 1966; 124: 166-75.
30. 131I labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-23.
31. 31. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984; 65: 305-11.
32. 32. Harms G, Dijkstra CD, Lee YC, Hardonk MJ. Glycosyl receptors in macrophage subpopulations of rat spleen and lymph node. A comparative study using neoglycoproteins and monoclonal antibodies ED1, ED2 and ED3. Cell Tissue Res 1990; 262: 35-40.
33. 33. Hines JE, Johnson SJ, Burt AD In vivo responses of macrophages and perisinusoidal cells to cholestatic liver injury. Am J Pathol 1997; 142: 511-8.
34. 34. Grinko I, Geerts A, Wisse E. Experimental biliary fibrosis correlates with increased numbers of fat-storing and Kupffer cells, and portal endotoxemia. J Hepatol 1995; 23: 449-58.
35. 35. Jansen RW, Kruijt JK, Van Berkel TJC, Meijer DKE Coupling of the antiviral drug ara-AMP to lactosaminated albumin leads to a specific uptake in rat and human hepatocytes. Hepatology 1993; 18: 146-52.
36. 36. Cerenzia MT, Fiume L, Venon WD, Lavezzo B, Brunetto MR, Ponzetto A, et al. Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology 1996; 23: 657-61.
37. 37. Pimstone NR, Stadalinik RC, Vera DR, Hutak DP, Trudeau WL. Evaluation of hepatocellular function by way of receptor-mediated uptake of a technetium-99m-labelled asialoglycoprotein analog. Hepatology 1994; 20: 917-23.
38. 38. Virgolini I, Muller C, Banyai M, Höbart J, Bergmann H, Pidlich J, et al. Imaging of the asialoglycoprotein receptor. In: Windler E, Greten H, editors. Hepatic Endocytosis of Lipids and Proteins. München: Zuckschwerdt Verlag; 1992. p. 166-70.
39. 99mTc-galactosyl-neoglycoalbumin (NGA) in alcoholic liver cirrhosis and liver fibrosis. Nucl Med Commun 1991; 12: 507-17.
40. 40. Meijer DKF, Keulemans K, Mulder GJ. Isolated perfused rat liver technique. Methods Enzymol 1981; 77: 81-94.
41. 41. Sawamura T, Kawasato S, Shiozaki Y, Sameshima Y, Nakada H, Tashiro Y. Decrease of a hepatic binding protein specific for asialoglycoproteins with accumulation of serum asialoglycoproteins in galactosamine-treated rats. Gastroenterology 1981; 81: 527-33.
42. 42. Burgess JB, Baenziger JU, Brown WR. Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis. Hepatology 1992; 15: 702-6.
43. 43. Bioulac Sage P, Kuiper J, Van Berkel TJ, Balabaud C. Lymphocyte and macrophage populations in the liver. Hepatogastroenterology 1996; 43: 4-14.
44. 44. Adams DH. Lymphocyte-endothelial cell interactions in hepatic inflammation. Hepatogastroenterology 1996; 43: 32-43.
45. 45. Friedman SL, Millward-Sadler GH, Arthur MJP. Liver fibrosis and cirrhosis. In: Millward-Sadler GH, Wright R, Arthur MJP, editors. Wright's Liver and Biliary Disease. Pathophysiology, Diagnosis and Management. London, Philadelphia, Toronto, Sydney, Tokyo: WB. Saunders Company Ltd.; 1992. p. 822-81.
46. 46. Swart PJ, Beljaars L, Smit C, Pasma A, Schuitemaker H, Meijer DKF. Comparative pharmacokinetics, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. J Drug Targeting 1996; 4: 109-16.
47. 47. Abraham R, Singh N, Mukhopadhyay A, Basu SK, Bal V, Rath S. Modulation of immunogenicity and antigenicity of proteins by maleylation to target scavenger receptors on macrophages. J Immunol 1995; 154: 1-8.
48. 48. Fiume L, Bassi B, Busi C, Mattioli A, Spinoza G. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-b-D-arabinofuranosyl-adenine 5́-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem Pharmacol 1986; 35: 967-72.
49. 49. Fiume L, Busi C, Preti P, Spinosa G. Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogenicity in mouse and rat. Cancer Drug Delivery 1987; 4: 145-50.
50. 50. Gressner AM, Bachern MG. Parasinusoidal lipocytes: their contribution to hepatic connective tissue synthesis and to the mechanisms of matrix amplification in fibrogenesis. In: Clément B, Guillouzo A, editors. Cellular and Molecular Aspects of Cirrhosis. Colloque INSERM/John Libbey Eurotext Ltd. 1992; 157-67.
51. 51. Friedman SL, Roll FJ, Boyles J, Bissell DM. Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 1985; 82: 8681-5.